Articles tagged with Messenger Rna
Researchers discovered a novel mechanism of intercellular communication through mRNA transfer between stem cells, allowing for biologically significant effects such as cell fate conversion and pluripotent state maintenance.
Researchers found that neurons conserve energy by regulating mRNA and protein number and location based on molecule length, longevity, and other properties. This helps minimize energy expenditure for synthesis, transport, and degradation.
A new biodegradable polymer-based delivery system efficiently transports mRNA, outperforming existing lipid nanoparticles in delivery efficiency and expression duration. The study also shows improved immune response results without liver accumulation or toxicity.
Researchers investigate how perturbed gene expression contributes to neurodegenerative disorders like Alzheimer's. Alternative polyadenylation, a mechanism regulating protein production, is being studied for its potential role in the disease.
Researchers have developed an mRNA cure for pre-eclampsia using a lipid nanoparticle, reducing maternal blood pressure and improving fetal health. The therapy, tested in pregnant mice, has shown promising results and is poised to move forward to human trials.
A novel mixture of mRNA in nanoparticles has been developed to protect therapeutic mRNA against degradation, improving its overall efficacy. The therapy stimulates the immune system to recognize and eliminate cancer cells while limiting detrimental side effects, also leading to immunological memory that protects against tumor rechallenge.
Researchers at the University of Ottawa have developed a nanoparticle strategy to deliver both mRNA and siRNA, enhancing and interfering with multiple gene and protein expressions. This approach holds significant promise for treating major diseases like cancer and cardiovascular diseases.
Professor Lutz Nuhn aims to create lipid-free capsules for RNA vaccines that don't require cooling and can initiate precise immune responses. He plans to equip the capsules with messenger substances to target cancer as well.
Researchers at Penn School of Engineering and Applied Science have developed a new method to refine ionizable lipids, key ingredients in lipid nanoparticles. This approach combines precision with rapid output, enabling safer and more effective mRNA vaccines and therapeutics.
A global team, including Lehigh University researcher Xuanhong Cheng, is exploring molecular- and cellular-level changes in muscle tissue that could lead to better diagnostic tools and therapeutic options for CFS and long COVID. The team aims to develop noninvasive diagnostic tools using electrical signatures.
A team of researchers has identified a mechanism that interferes with the splicing process in a more subtle way, leading to cell death. The study reveals that spliceosome subunits U4, U5, and U6 are normally stabilized by protein USP39, but when mutated or absent, stability is compromised, causing incorrect connections during splicing.
A randomized clinical trial found that simultaneous administration of mRNA COVID-19 and inactivated influenza vaccines had comparable reactogenicity to sequential administration. This suggests a safe option for co-administration of these vaccines.
The non-GMP NATi mRNA BioFoundry in Singapore is a first-of-its-kind facility dedicated to mRNA manufacturing. It will support the country's ambition of becoming a leading hub for biomedical innovation and strengthen its leadership in nucleic acid therapeutics.
A new study in mice shows a unique mRNA delivery method can successfully edit faulty genes in fetal brain cells. The technology has the potential to stop progression of genetic-based neurodevelopmental conditions like Angelman syndrome and Rett syndrome before birth.
The Max Planck Institute team has developed a strategy to extend mRNA lifespan by protecting it from degradation. This protects potentially health-promoting proteins, such as tumor suppressors and nuclear receptors, from premature breakdown.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have discovered a novel means of directing lipid nanoparticles to target specific tissues. By incorporating siloxane composites into ionizable lipids, they were able to achieve tissue-specific delivery, particularly to the liver, lungs, and spleen.
Researchers from Japan have discovered that Exportin-5 interacts with a broader spectrum of RNAs, including tRNAs, miRNAs, lncRNAs, and specific mRNAs. This study sheds light on the unique roles of Exp5 in RNA export within Drosophila cells.
A new mpox mRNA vaccine has shown improved responses in nonhuman primate models, reducing symptoms and disease duration compared to a currently licensed modified vaccinia Ankara (MVA) vaccine. The investigational vaccine resulted in fewer lesions, shorter disease duration, and lower viral shedding.
Patients with post-COVID-19 mRNA vaccination myocarditis show lower cardiovascular complications at 18 months compared to those with conventional myocarditis. However, affected patients may require medical management for several months after hospital discharge.
A recent study investigated COVID-19 vaccine exposure in the first trimester and its potential impact on major structural birth defects. The results indicate that mRNA COVID-19 vaccine exposure during this period is not associated with an increased risk for selected birth defects among live births.
A research team from Göttingen University has discovered that antisense RNA (asRNA) plays a crucial role in cell transport, allowing cells to accelerate gene expression and produce proteins quickly in response to environmental stress or harm. This new understanding sheds light on the function of asRNAs and their potential link to disea...
The CCR4-NOT complex plays a crucial role in regulating RNA metabolism and stress response in C. elegans, compromising stress resistance and decreasing lifespan when depleted of subunits. This study highlights an important new role for the CCR4-NOT complex in normal aging and longevity.
Researchers developed a method to quantify mRNA transcription and degradation rates within individual cell types, uncovering varied regulatory rates across genes. The study provides novel insights into how pluripotent cells adopt specialized identities through gene expression.
Researchers developed a simple and efficient method for diversifying reactive end-groups on poly(2-oxazoline)s, enabling rapid exploration of poly(2-oxazoline)-based nanomedicine platforms. The approach was shown to produce POx-based lipid nanoparticles comparable in transfection capability to their PEGylated counterparts.
Researchers identify TRMT10C enzyme causing methylation of ND5 mRNA, leading to mitochondrial dysfunction and reduced energy supply to the brain. Impairment of complex I in the respiratory chain contributes to Alzheimer's disease pathology.
Researchers at Tokyo Medical and Dental University have developed a novel method for coating engineered messenger RNA molecules with polyethylene glycol (PEG), allowing selective delivery to the spleen. This breakthrough enables fine-tuned control over mRNA therapy, facilitating effective treatment of diseases previously considered inc...
A recent study published in JAMA found that bivalent mRNA COVID-19 vaccines were highly effective in protecting against SARS-CoV-2 infection and symptomatic COVID-19 in children and adolescents aged 5 to 17. The study, involving 2,959 participants, demonstrated the significant benefit of COVID-19 vaccination in this age group.
A large population-based study found that COVID-19 mRNA vaccines were not associated with increased neonatal adverse events in infants born between June 2021 and January 2023. The study included 94,000 vaccinated infants and 102,000 control infants, indicating a lower risk of serious health issues.
A large study of nearly 200,000 newborns in Sweden and Norway found that COVID-19 vaccination during pregnancy was not associated with any increased risks in newborn infants. In fact, babies born to vaccinated mothers had lower mortality rates and fewer serious complications.
Researchers aim to decipher function and structure of 1,000 RNA-binding proteins involved in mRNA transport. They hope to gain insights into mRNA stability, relevant to new vaccine development and cancer research.
Researchers found a code directing mRNAs to specific neighborhoods for translation, revealing the cytoplasm's compartmentalization. This discovery sheds light on fundamental cellular biology and holds promise for increasing or altering protein production in mRNA vaccines and therapies.
Plant scientists have discovered a sophisticated RNA defense system that plants use to attack gray mold cells, sending mRNA molecules that disrupt fungal cellular processes. This innovative approach could lead to the development of eco-friendly fungicides with minimal environmental impact and no harm to humans or animals.
Scientists in Germany developed a new analytical method to precisely elucidate the size of particles, structure, and RNA molecules in pharmaceutical products. This information can help evaluate product quality, enabling improved development of new products.
Researchers have developed a mineral coating that maintains mRNA activity for up to six months at room temperature. This breakthrough enables the storage of mRNA therapeutics like COVID-19 vaccines on medical shelves, bridging the gap between rich and poor communities.
A team of researchers at Hokkaido University has discovered a new role for 4.5 SH RNA in mice, which plays a crucial role in regulating alternative splicing and may be the first identified member of a new class of regulatory RNAs.
A new stem cell treatment using mRNA technology from COVID-19 vaccines has shown promise in regenerating liver tissue, potentially reversing chronic and acute liver diseases. The treatment stimulates the natural repair mechanism of the liver by activating specific receptors on stem cells.
Researchers have identified a sequence within therapeutic mRNAs that causes unintended immune responses and found a way to correct these errors. By designing 'slip-resistant' mRNAs, the team aims to produce future mRNA vaccines with improved safety and efficacy.
An mRNA SARS-CoV-2 vaccination before vs. during pregnancy and omicron infection among infants study found that maternal vaccination during the antenatal period was associated with a lower risk of Omicron SARS-CoV-2 infection in infants up to six months of age.
The study found co-administration of the Pfizer-BioNTech COVID-19 vaccine with the seasonal influenza vaccine to be effective in preventing COVID-19 and flu-related outcomes. This may improve vaccination uptake for both vaccines.
A study of 142,000 live births found that maternal mRNA COVID-19 vaccination during pregnancy was associated with reduced risks of severe neonatal morbidity, neonatal death, and intensive care unit admission. No increase in hospital admissions or readmissions up to age six months was observed.
A primary mRNA vaccine series offers significant protection against SARS-CoV-2 infection in Singaporean children aged 1-4. The study found a low incidence of hospitalization and severe illness, but highlights the potential benefits of vaccination in preventing infection and sequelae.
Researchers developed a new base modification, Z-mRNA, that demonstrates low immunogenicity and reduced cytotoxicity compared to unmodified mRNAs. The modified mRNA can induce a substantial immune response and has potential therapeutic applications beyond COVID-19 vaccines.
A team from Tokyo Medical and Dental University has developed a technique to improve bone regeneration over large areas in rats, using vascular endothelial growth factor (VEGF) and Runx2. The combination of these two RNAs led to better regenerative responses in bone cells than each RNA alone.
Researchers detected distinct RNA patterns in healthy and preeclampsia-affected pregnancies, identifying messenger RNA, microRNA, and long noncoding RNA as potential biomarkers. The study developed classifiers for predicting preterm and early-onset preeclampsia with high accuracy.
Researchers identified OBOX genes as master regulators of zygote genome activation, enabling the newly formed embryo to develop according to its own genetic program. The study found that these genes facilitate Pol II locating to the correct genes, allowing for the activation of transcription factors and subsequent development.
Molecular biologists Ruslan Afasizhev and Inna Afasizheva have discovered the architecture of molecular machines involved in RNA editing in a disease-causing parasite. This understanding could potentially help treat African sleeping sickness, which is usually fatal and has limited treatment options.
Studies showed mRNA vaccines provided long-term immunity against severe COVID-19 outcomes in cancer patients. The study found waning immunity after up to 4 mRNA vaccine doses, highlighting the need for booster shots.
Researchers have developed a method to produce highly active mRNA vaccines at high purity using a unique cap to easily separate the desired capped mRNA. This 'Purecap' technique extracted up to 100% pure Cap2-type mRNA, which showed improved protein production and lower immunostimulatory activity.
A prospective study of COVID-19 mRNA vaccines found progressively declining immune functions in individuals with chronic lymphocytic leukemia (CLL). The study, published in PLOS Medicine, showed that CLL patients experienced reduced antibody responses to the vaccines.
A German federal funding program will support a five-year research collaboration to develop specialty lipids and auxiliaries for mRNA vaccines. The project aims to enhance production capacities and improve the resilience of supply chains for future mRNA therapeutics.
Researchers at Karolinska Institutet have developed a new method called single-particle profiling (SPP) to study bioparticles in health and disease. The SPP enables the measurement of thousands of particles between 5 and 200 nanometres in size, with potential applications in vaccine development and creating more effective nanocarriers.
A new research centre will focus on developing new types of RNA medicine for treating metabolic diseases. The centre, led by Professor Jørgen Kjems at Aarhus University, aims to create targeted treatments for conditions like diabetes and atherosclerosis.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
Researchers discovered a protein complex called FERRY that plays a crucial role in transporting messenger RNA in neurons. The study provided evidence of the transport of mRNA using Early Endosomes (EEs) and a novel mode of binding RNA via coiled-coil domains.
Researchers at the Max Planck Institute found that ghrelin activates specialized nerve cells in the amygdala, promoting food consumption and conveying hunger feelings. The study uncovers the physiological processes behind feeding behavior, which may lead to novel therapeutic approaches for eating disorders.
Researchers have cloned the wheat rust resistance genes Lr9 and Sr43, revealing that they encode unusual kinase fusion proteins. This breakthrough enables new options for addressing disease resistance in bread wheat and could lead to heat-resistant versions of the Sr43 gene to adapt to climate change.
Researchers found that a mutation in RPL3L, expressed only in heart and skeletal muscle, leads to impaired cardiac contractility by causing ribosomal collisions and protein folding abnormalities. The study aims to develop new treatments for cardiomyopathy and atrial fibrillation.
Researchers at the Max Planck Institute found that specific start sites (TSSs) are linked to distinct end sites (TESs), shaping the RNA landscape unique to each tissue. Dominant promoters, which overrule conventional signals, drive this process and are conserved across species.
Researchers have discovered a novel feature of long intergenic noncoding RNAs (lincRNAs) that can serve as markers indicating specific types of tissue. This finding has the potential to lead to highly specific disease treatments by targeting diseased tissues.
Researchers from Graz University of Technology have developed a novel method for producing central components of mRNA vaccines using biocatalytic synthesis. This approach achieves a yield of 92-95% compared to 40-50% for chemical processes, making it more efficient and cost-effective.